Lilly(Eli) & Company
NYSE: LLY
$887.16
+$1.61 (+0.2%)
Closing Price on October 4, 2024
LLY Articles
With oil plunging, and the market reeling from what should prove to be extremely good news for consumers, many investors are in a quandary over which path to take for 2016.
Published:
Last Updated:
Wednesday's top analyst upgrades, downgrades and initiations include Agilent, CSC, Intel, Jabil Circuit, Kinder Morgan, Nasdaq, Square and Yahoo.
Published:
Last Updated:
Brokerage firm Jefferies has released its top pharmaceutical picks for the coming year and what to expect.
Published:
Last Updated:
Monday's top analyst upgrades, downgrades and initiations include Abbott Labs, Bluebird Bio, Chipotle, Eli Lilly, Ferrari and Wells Fargo.
Published:
Last Updated:
Tuesday's top analyst upgrades, downgrades and initiations include AbbVie, CDW, CSC, Eli Lilly, Ericsson, Gold Fields, JD.com, Nokia and Rackspace.
Published:
Last Updated:
Despite the howling from political candidates trying to make the top drug-makers their whipping boy in populist campaign efforts, the need and demand for pharmaceuticals will only continue. This...
Published:
Last Updated:
Jefferies has updated the thesis behind its "Top 5 for 2015" pharmaceutical stock picks
Published:
Last Updated:
Monday's top analyst upgrades, downgrades and initiations include Best Buy, CA, Deere, Eli Lilly, Ferrari, Netflix, Oracle and Salesforce.com.
Published:
Last Updated:
24/7 Wall St. screened the Merrill Lynch research universe for pharmaceutical stocks paying solid dividends that are rated Buy, and found four outstanding companies.
Published:
Eli Lilly reported mixed third-quarter financial results on Thursday before the markets opened.
Published:
Last Updated:
Eli Lilly is scheduled to report its third-quarter earnings before the markets open on Thursday.
Published:
While there were many winners, last week brought a lot of truly bad news or bad reactions for some of the large cap stocks in the market.
Published:
Eli Lilly is suffering after bad news about its evacetrapib for high-risk atherosclerotic cardiovascular disease.
Published:
Credit Suisse sees solid upside in this company Eli Lilly as the result of a strong pipeline, with its Alzheimer's candidate as a potential blockbuster.
Published:
Friday's top analyst upgrades, downgrades and initiations include AT&T, BioCryst Pharmaceuticals, Eli Lilly, Facebook, Flextronics, Gap and Tesla Motors.
Published: